HCW Biologics Inc. (NASDAQ:HCWB) Short Interest Up 905.4% in February

HCW Biologics Inc. (NASDAQ:HCWB) was the recipient of a significant increase in short interest in February. As of February 15th, there was short interest totalling 835,500 shares, an increase of 905.4% from the January 31st total of 83,100 shares. Approximately 3.6% of the shares of the stock are short sold. Based on an average trading volume of 6,100,000 shares, the days-to-cover ratio is presently 0.1 days.

HCW Biologics Stock Up 3.8 %

Shares of HCW Biologics stock opened at $0.38 on Friday. HCW Biologics has a 12-month low of $0.21 and a 12-month high of $2.52. The firm has a market capitalization of $16.88 million, a PE ratio of -0.38 and a beta of 0.81. The stock’s fifty day moving average is $0.39 and its 200-day moving average is $0.47.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.